RE:Th1902-Yes, but it seems like it is a 2024 story as the objective of getting to cash flow positive this year probably negates any significant spending on TH-1902 this year. Hopefully, the new effort to target healthier patients and tumors where TH-1902 has already shown activity with smaller, more frequent doses will be accepted by the FDA and will work.